Jim Simons Biomarin Pharmaceutical Inc Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 895,771 shares of BMRN stock, worth $51.1 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

895,771

Previous 435,871 105.51%

Holding current value

$51.1 Million

Previous $28.6 Million 121.03%

% of portfolio

0.1%

Previous 0.05%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$61.25 - $72.83 $28.2 Million - $33.5 Million	459,900 Added 105.51%	895,771 $63.3 Million
Q4 2024 Feb 13, 2025	BUY	$61.93 - $70.49 $1.05 Million - $1.2 Million	17,000 Added 4.06%	435,871 $28.6 Million
Q3 2024 Nov 13, 2024	BUY	$69.02 - $93.84 $20.9 Million - $28.4 Million	302,671 Added 260.47%	418,871 $29.4 Million
Q2 2024 Aug 09, 2024	SELL	$74.43 - $92.22 $31.7 Million - $39.3 Million	-425,871 Reduced 78.56%	116,200 $9.57 Million
Q1 2024 May 13, 2024	BUY	$83.81 - $99.0 $13 Million - $15.4 Million	155,400 Added 40.19%	542,071 $47.3 Million
Q4 2023 Feb 13, 2024	SELL	$76.22 - $98.51 $14.9 Million - $19.2 Million	-195,100 Reduced 33.54%	386,671 $37.3 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $12.8 Million - $14.3 Million	-150,867 Reduced 20.59%	581,771 $51.5 Million
Q2 2023 Aug 11, 2023	SELL	$86.68 - $100.3 $4.2 Million - $4.86 Million	-48,433 Reduced 6.2%	732,638 $63.5 Million
Q1 2023 May 12, 2023	BUY	$87.74 - $117.27 $13.2 Million - $17.7 Million	150,800 Added 23.93%	781,071 $76 Million
Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $9.24 Million - $12.4 Million	-114,200 Reduced 15.34%	630,271 $65.2 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $797,609 - $941,093	9,708 Added 1.32%	744,471 $63.1 Million
Q2 2022 Aug 12, 2022	BUY	$71.48 - $86.85 $17.4 Million - $21.2 Million	243,592 Added 49.59%	734,763 $60.9 Million
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $11.9 Million - $14.8 Million	-159,889 Reduced 24.56%	491,171 $37.9 Million
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $19.3 Million - $24.7 Million	269,589 Added 70.67%	651,060 $57.5 Million
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $6.84 Million - $7.82 Million	91,500 Added 31.55%	381,471 $29.5 Million
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $5.71 Million - $6.41 Million	-75,600 Reduced 20.68%	289,971 $24.2 Million
Q1 2021 May 13, 2021	BUY	$74.73 - $90.69 $27.3 Million - $33.2 Million	365,571 New	365,571 $27.6 Million
Q2 2020 Aug 13, 2020	SELL	$79.55 - $124.22 $1.52 Million - $2.37 Million	-19,100 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$71.37 - $96.85 $13.1 Million - $17.8 Million	-183,371 Reduced 90.57%	19,100 $1.61 Million
Q4 2019 Feb 13, 2020	SELL	$64.27 - $86.37 $22.7 Million - $30.5 Million	-353,600 Reduced 63.59%	202,471 $17.1 Million
Q3 2019 Nov 13, 2019	BUY	$67.4 - $85.11 $1.26 Million - $1.59 Million	18,700 Added 3.48%	556,071 $37.5 Million
Q2 2019 Aug 12, 2019	BUY	$80.35 - $93.9 $17.3 Million - $20.2 Million	215,400 Added 66.9%	537,371 $46 Million
Q1 2019 May 14, 2019	BUY	$84.2 - $98.62 $23.4 Million - $27.5 Million	278,400 Added 638.96%	321,971 $28.6 Million
Q4 2018 Feb 13, 2019	BUY	$80.14 - $106.07 $3.49 Million - $4.62 Million	43,571 New	43,571 $3.71 Million

Others Institutions Holding BMRN

# of Institutions

669

Shares Held

184M

Call Options Held

1.24M

Put Options Held

957K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.6B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account